KDR and glioblastoma: Allen et al. investigated the efficacy of combination therapy of anti-PD-L1 (anti-PD-L1 mAb: B20S) and anti-VEGFR2 (anti-VEGFR2 mAb: DC101) in mice bearing pancreatic neuroendocrine tumor, mammary carcinoma, and glioblastoma [79].